Back to Authors

Weissman, Scott J.

0000-0002-3755-4010

Mayo Clinic

Seattle Children's Research Institute

Citations 3

Correction for Hasassri et al., An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase
Hasassri, M. Earth , Boyce, Thomas G. , Cunningham, Scott A. , Patel, Robin , Banerjee, Ritu , Pogue, Jason M. , Kaye, Keith S. , Norgan, Andrew P. , Jeraldo, Patricio R , Jeraldo, Patricio , Weissman, Scott J. , Patel, Robin , Cunningham, Scott A

Antimicrobial Agents and Chemotherapy | July 22, 2016 | Volume: 60 | Issue: 8 | Pages: 5108-5108

10.1128/aac.01338-16 Get It

An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase
Hasassri, M. Earth , Boyce, Thomas G. , Norgan, Andrew P. , Cunningham, Scott A. , Jeraldo, Patricio , Patel, Robin , Banerjee, Ritu , Pogue, Jason M. , Kaye, Keith S. , Jeraldo, Patricio R , Weissman, Scott J. , Patel, Robin , Norgan, Andrew P , Cunningham, Scott A

Antimicrobial Agents and Chemotherapy | May 24, 2016 | Volume: 60 | Issue: 6 | Pages: 3270-3275

10.1128/aac.03118-15 Get It

ABSTRACT We describe a 16-year-old neutropenic patient from the Middle East with bloodstream infection caused by two carbapenemase-producing Escherichia coli isolates that we characterized by whole-genome sequencing. While one displayed meropenem resistance and was bla NDM positive, the other demonstrated meropenem susceptibility yet harbored bla OXA181 (which encodes a bla OXA48 -like enzyme). This report highlights the challenge of laboratory detection of bla OXA48 -like enzymes and the clinical implications of genotypic resistance detection in carbapenemase-producing Enterobacteriaceae .
Antimicrobial Stewardship in Pediatric Care: Strategies and Future Directions
Newland, Jason G. , Banerjee, Ritu , Gerber, Jeffrey S. , Hersh, Adam L. , Steinke, Leah, Weissman, Scott J.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | September 5, 2012 | Volume: 32 | Issue: 8 | Pages: 735-743

10.1002/j.1875-9114.2012.01155.x Get It

Antimicrobial stewardship programs (ASPs) are an effective strategy for improving the quality and safety of antimicrobial prescribing for hospitalized patients. Pediatric ASPs are in their early stages of development, and there are unique issues relevant to children. The imperative to ensure that antimicrobials are prescribed judiciously is highlighted by the ongoing epidemic increase in antimicrobial‐resistant infections and the simultaneous decline in the rate of new drug development. In this review we describe the process of ASP development for pediatrics, review existing data regarding the impact of pediatric ASPs, and describe the priorities and challenges for ASP research including study design and appropriate end points.